Trial Search Results
TRIAD - Treatment of Insomnia and Depression
The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.
Stanford is currently not accepting patients for this trial.
Collaborator: University of Pennsylvania
- Drug: Antidepressant
- Behavioral: Desensitization Therapy for Insomnia
- Behavioral: Cognitive Behavioral Therapy for Insomnia
Phase 2/Phase 3
1. Meets criteria for Major Depressive Disorder
2. Between 18 and 75 years of age and adequately fluent in English
3. Meets criteria for an insomnia disorder
1. Women who are currently pregnant, breast-feeding, or not using a reliable birth
2. People for whom the antidepressant medication(s) provided in the study is not
3. People who have had minimum adequate trials of (or have not been able to tolerate) all
three study medications.
4. People with uncontrolled medical conditions.
5. People with moderate or severe sleep disorders other than insomnia
6. Individuals on a fixed night shift or rotating work schedule that requires a night
7. Patients with a current principal diagnosis of a psychiatric disorder that
necessitates treatment that is not offered in the study.
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study